A Phase 2a open-label trial evaluates the safety and antidepressant efficacy of inhaled mebufotenin (GH001), a rapid-acting 5-HT agonist, in adult patients with postpartum depression.
An expert panel recommends regular review of psychotropic medications to optimize prescribing practices and patient safety.
A clinical trial is recruiting to evaluate lumateperone for the treatment of late-life depression and treatment-resistant depression.
A clinical trial is evaluating an investigational probiotic preparation for the treatment of PTSD, representing a novel microbiome-targeted therapeutic approach for a psychiatric condition.
A feasibility trial suggests ketogenic dietary therapy is safe and may reduce core symptoms of anorexia nervosa in adults, offering a potential non-pharmacologic treatment option.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Oct 02 – Jun 03)
- Consider early tapering from opioid agonist treatment only with extreme caution, as it significantly increases all-cause mortality risk compared to maintaining treatment for 12-48 months.
- Utilize the 2025 Japanese Expert Consensus to guide symptom-specific antipsychotic selection in schizophrenia, prioritizing brexpiprazole, aripiprazole, or olanzapine based on individual side-effect profiles.
- Monitor pediatric patients closely for non-persistence and adverse events when prescribing dopamine D2 receptor modulators for Tourette syndrome, as real-world data shows high discontinuation rates.
- Incorporate pharmacogenomic testing to explain non-response to ADHD medications and optimize stimulant prescribing decisions when standard titration fails.
- Reinforce lithium monotherapy as a first-line maintenance treatment for bipolar disorder, supported by nationwide cohort studies confirming its efficacy for long-term management.
- Evaluate the potential of clozapine for severe irritability in adolescents with autism spectrum disorder, using real-world evidence from comparative studies with schizophrenia patients to inform off-label prescribing.
- Review the British Association for Psychopharmacology consensus guidelines for evidence-based pharmacological management of substance dependence to update current treatment protocols.
- Consider the safety profile of inhaled mebufotenin as a rapid-acting 5-HT agonist for postpartum depression, noting its evaluation in Phase 2a trials for potential rapid antidepressant effects.
- Be aware that incident benzodiazepine and Z-drug use is associated with an increased risk of subsequent alcohol- and drug-related problems, warranting careful risk-benefit analysis for new prescriptions.
- Explore repurposing opportunities for existing non-psychiatric drugs like ACE inhibitors and metformin for major depression, based on Mendelian randomization studies identifying novel drug targets.
Drug Development 2
Optimi Health has completed commercial production of psilocybin in Australia, marking a significant step in the supply chain for investigational treatments of treatment-resistant depression.
Optimi Health has completed Good Manufacturing Practice production of psilocybin capsules, marking a manufacturing milestone for a psychedelic compound currently under investigation for psychiatric indications.
Policy & Regulation 3
Australia has authorized the prescription of psilocybin for treatment-resistant depression, marking a significant regulatory shift for this psychedelic psychiatric treatment.
The Australian TGA has rejected a proposal to reschedule psilocybin, maintaining its current regulatory status and limiting its use to approved clinical trials rather than general medical practice.
FDA issued a Complete Response Letter for Cingulate's CTx-1301, a timed-release dexmethylphenidate formulation for ADHD, citing manufacturing deficiencies rather than safety or efficacy concerns.
Diagnosis & Treatment 4
This systematic review of international guidelines identifies core components for early intervention in psychosis, emphasizing cautious antipsychotic use for clinical high-risk patients and structured pharmacological monitoring for first-episode psychosis.
An integrated treatment model for schizophrenia and opioid use disorder demonstrated high medication adherence and significant reductions in hospitalizations and ED visits, highlighting the importance of coordinated pharmacotherapy for this dual-diagnosis population.
A small study of 19 patients with treatment-resistant depression found psilocybin was associated with significant symptom reduction, highlighting its potential as a novel therapeutic agent.
A study links psilocybin to a reduction in depression symptoms, highlighting its potential as a novel therapeutic agent for mood disorders.
Neuroscience 1
A study reveals that deep brain stimulation (DBS) remodels white matter pathways and alters neural networks, providing a biological mechanism for its efficacy in severe depression.
Pharmacogenomics 3
A new pharmacogenomic test is available to help explain non-response to ADHD medications, offering a clinical tool for optimizing stimulant prescribing.
New pharmacogenomic testing is available to help explain individual variability in response to ADHD medications, offering a clinical tool for optimizing prescribing decisions.
This meta-analysis synthesizes current evidence on genetic factors associated with antipsychotic-induced weight gain in adults with severe mental illness, highlighting the role of pharmacogenomics in predicting this adverse effect.
Substance Use 1
Early tapering from opioid agonist treatment (methadone or buprenorphine/naloxone) increases taper completion rates but significantly raises all-cause mortality risk compared to waiting 12-48 months.
Podcast Summary 1
A leading PTSD expert critiques the limited efficacy of SSRIs for PTSD and discusses the evolving landscape of treatments including MDMA, psilocybin, and virtual reality exposure therapy.
Digital Health 1
A clinical trial is recruiting to evaluate the feasibility of transcranial ultrasound stimulation as a treatment for schizoaffective disorder.
Clinical Pearl 2
A real-world study of pediatric Tourette syndrome patients reveals high non-persistence with dopamine D2 receptor modulators and significantly increased odds of adverse events and healthcare utilization compared to non-treated peers.
A randomized, double-blind, placebo-controlled trial evaluates the efficacy of cannabidiol for managing behavioral and psychological symptoms of vascular dementia.
Mechanism of Action 2
Preclinical study demonstrates that psilocybin reduces neuropathic pain behaviors in mice and enhances the analgesic effects of gabapentin, suggesting a potential mechanistic basis for psilocybin's role in pain modulation.
A double-blinded placebo-controlled study investigates the impact of psilocybin on subjective and objective time perception, contributing to the mechanistic understanding of psychedelic effects relevant to psychiatric treatment.
Journal Article 3
This retrospective study compares the clinical profiles and treatment outcomes of clozapine in adolescents with schizophrenia versus those with autism spectrum disorder, providing real-world evidence for its off-label use in severe ASD irritability.
A case register study reinforces lithium monotherapy as a first-line maintenance treatment for bipolar disorder, supporting its continued use for long-term pharmacological management.
A nationwide matched cohort study with co-twin comparison investigates the association between incident benzodiazepine and Z-drug use and the subsequent risk of developing alcohol- and drug-related problems.